<DOC>
	<DOCNO>NCT02133521</DOCNO>
	<brief_summary>This prospective , randomize , double-blind , control clinical study investigate effect DLBS1033 conjunction standard therapy compare standard therapy alone acute ischemic stroke patient . It hypothesize improvement functional outcome measure NIHSS BI well improvement haemostatic parameter measure thrombocyte aggregation test ( TAT ) , fibrinogen , d-dimer DLBS group significantly great control group .</brief_summary>
	<brief_title>DLBS1033 Acute Ischemic Stroke Patients</brief_title>
	<detailed_description>Subjects study screen consecutively eligible subject randomize two group receive investigational drug , DLBS1033 dose 490 mg three time daily placebo addition standard therapy 28-days course therapy . Standard therapy use study consist : aspirin 80 mg , simvastatin 20 mg , vitamin B complex . After hospital admission diagnosis , patient handle per acute ischemic stroke management study site . Right patient confirm eligible study , treatment ( ) switch immediately study treatment . Clinical laboratory examination evaluate investigational drug 's efficacy perform baseline 3 , 7,14 , 28 day study medication initiation ; safety examination perform time point , 3 14 day study medication initiation .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Signed informed consent patient patient ' legally acceptable representative ( must obtain trial related activity ) . Male female subject age 1865 year Screening . Patients clinically diagnose acute ischemic stroke attack confirm CT scan . Patients cerebral infarction subtypes PACI LACI classify Bamford criterion . Patients moderate condition base National Institutes Health Stroke Scale ( NIHSS ) score 515 . Patients present hospital receive first dose study medication within 72 hour onset stroke symptom . Able take oral medication . For female childbearing potential : pregnancy lactation period . History hemorrhagic stroke within last 3 month . Patients seizure onset stroke regular medication seizure/epilepsy . Current regular use ( within last 1 month ) oral anticoagulant , antiplatelets study medication , herbal medicine . Patients receive tissue plasminogen activator ( TPA ) within 24 hour Screening . History serious head injury within last 3 month . History major surgery within last 3 month . Recent serious cardiovascular condition , myocardial infarction heart atrial fibrillation demonstrate electrocardiography ( ECG ) . History congestive heart failure aortic dissection . Presence severe renal hepatic dysfunction , define serum creatinine level &gt; 3x upper limit normal ( ULN ) history hemodialysis , serum ALT , AST , GammaGT level &gt; 3x ULN , respectively . Presence acute SIRS . Presence chronic infection . Patients higher risk bleed . Subjects uncontrolled hypertension ( systolic blood pressure &gt; 185 mmHg diastolic blood pressure &gt; 110 mmHg ) . Subjects random plasma glucose ≥180 mg/dL HbA1c ≥ 7.0 % Screening . Known suspect hypersensitivity trial product relate product . Participation clinical study within 30 day prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>DLBS1033</keyword>
	<keyword>Acute ischemic stroke</keyword>
	<keyword>NIHSS</keyword>
	<keyword>Barthel Index</keyword>
</DOC>